在法布里病中使用酶替代疗法:一种随机对照试验
R Schiffmann1, J B Kopp, H A Austin
1Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bldg 10, Room 3D03, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892-1260, USA. rs4e@nih.gov
JAMA
|June 21, 2001
概括
在患有法布里病的患者中,用α-galactosidase A (alpha-gal A) 的酶替代疗法显著降低了神经病痛,改善了功能. 这种静脉注射治疗为管理这种罕见的代谢障碍提供了安全有效的选择.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 费布里病是一种罕见的遗传代谢障碍,由α-galactosidase A (alpha-gal A) 缺乏引起.
- 目前的管理缺乏特定的治疗方法,导致严重的并发症,如神经病痛,功能衰竭和心血管问题.
研究的目的:
- 评估静脉注射alpha-gal A酶替代疗法对法布里病的安全性和疗效.
- 评估alpha-gal A对神经病痛和关键器官功能的影响.
主要方法:
- 这是一项双盲,安慰剂控制的试验,涉及26名已成年男性患者,他们已确认患有法布里病.
- 患者每隔一周内静脉注射alpha-gal A (0.2 mg/kg),服用12剂.
- 使用简要疼痛清单 (BPI) 评估神经病痛,同时评估功能和心脏导电.
主要成果:
- 与安慰剂相比,α-gal A组的神经病痛评分 (BPI) 显著降低,与疼痛相关的生活质量有所改善.
- 组织学分析显示,治疗患者的球体中膜扩张减少 (P=.01).
- 观察到肌素清除 (P=0.02),血糖脂水平,心脏导电和体重的改善.
结论:
- 静脉注射alpha-gal A是法布里病的安全治疗选择.
- 酶替代疗法证明了广泛的疗效,缓解疼痛和改善多个器官系统功能.
- 这项研究支持酶替代疗法作为法布里病的可行治疗策略.
相关概念视频
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...


